Leaked news on Cologuard test boosts Exact Sciences stock
According to
The article says the
Analyst
With the update,
"We are aware that the
Last October, the USPSTF issued draft guidelines that designated Exact's non-invasive, DNA-based stool test, Cologuard, as an alternative test, useful in "select clinical circumstances," rather than one of the main screening tests suggested.
The company's stock fell nearly 50 percent in response to the draft report.
On Wednesday, though, Exact stock hit a high of
___
(c)2016 The Wisconsin State Journal (Madison, Wis.)
Visit The Wisconsin State Journal (Madison, Wis.) at www.wisconsinstatejournal.com
Distributed by Tribune Content Agency, LLC.
Advisor News
Annuity News
Health/Employee Benefits News
Life Insurance News